Drugs / [99mTc]Tc-DB8
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05940298 | Jul 2023 → Jun 2024 | breast cancer, prostate cancer | Tomsk National Research Medical Center of the Russian Academy of Sciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07275463 | Oct 2025 → Dec 2026 expected | breast cancer | Tomsk National Research Medical Center of the Russian Academy of Sciences | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [99mTc]Tc-DB8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07275463 ↗ |
| Route | Intravenous | “One single intravenous injection of \[99mTc\]Tc-DB8” NCT05940298 ↗ |